Zhejiang Hisoar Pharmaceutical Co Ltd

Zhejiang Hisoar Pharmaceutical Co Ltd has a debt-to-equity ratio of 0.26, indicating a relatively conservative capital structure with a strong equity base. The company's current ratio of 1.28 suggests it has sufficient short-term assets to cover its short-term liabilities, though it is not significantly overcapitalized in the short term. However, the company's operating cash flow is negative at -59.68 million CNY, and its free cash flow is positive at 145.51 million CNY, suggesting that capital expenditures are being funded by operational cash flows. The company's profitability is weak, with a return on equity of -1.81% and a return on assets of -1.24%, both of which are below the typical thresholds for a healthy pharmaceutical firm. These metrics indicate that the company is not generating returns that meet the cost of equity or assets, which is a concern for investors. The operating income is negative at -78.45 million CNY, and the net income is also negative at -91.08 million CNY, further highlighting the company's financial challenges. Zhejiang Hisoar Pharmaceutical Co Ltd's revenue is concentrated in a single geographic market, primarily China, as disclosed in its financial statements. There is no indication of significant international operations or diversified revenue streams, which increases the company's exposure to domestic economic and regulatory risks. The company's revenue for the latest period is 1.86 billion CNY, but the lack of segment reporting makes it difficult to assess the performance of individual product lines or therapeutic areas. The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current fiscal year. The operating income and net income are both negative, and there is no provided outlook for the next fiscal year. The company's capital expenditures are -74.46 million CNY, which may indicate a reduction in investment in new facilities or equipment. The company's liquidity is rated as medium, and the risk assessment indicates a low potential for dilution, though the company has negative net cash after subtracting total debt. Recent events and filings do not provide specific details on the company's strategic initiatives or financial developments. The company's ESG scores indicate a moderate level of social responsibility and governance, with a social pillar score of 30.27 and a governance pillar score of 59.12. However, the ESG controversies score is 100.00, suggesting that the company has not been involved in any major controversies. The company's recent financial performance and risk profile suggest that it is facing significant operational and financial challenges. The negative operating and net income, combined with a weak return on equity and assets, indicate that the company is not currently generating value for its shareholders. The company's liquidity position is moderate, and while the potential for dilution is low, the negative net cash position is a concern.